Makers of the "morning after pill" Plan B. Hmmmm....
Who's got my Xannies?
Barr Receives Approval for Generic XANAX XR(R) Tablets
WOODCLIFF LAKE, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer Inc.'s XANAX XR(R) (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The Company intends to launch its product immediately.
XANAX XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.
Barr's Alprazolam Extended-Release tablets will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.